Longeveron to Announce Third Quarter 2022 Financial Results on November 14, 2022

Rhea-AI Summary

Longeveron Inc. (NASDAQ: LGVN) is set to release its Q3 2022 financial results on November 14, 2022, prior to U.S. market opening. The company will host a conference call at 8:30 a.m. EST to discuss these results and provide a corporate update. The company is developing regenerative medicines, focusing on its lead product, Lomecel-B™, for conditions like Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and Aging Frailty. Interested parties can access the call via dial-in or through a webcast on the Longeveron website.

Positive

• Longeveron's lead product, Lomecel-B™, is advancing through clinical trials for multiple indications.
• Upcoming Q3 financial results may provide insights into the company's progress and future potential.

Negative

• None.

Live conference call on Monday, November 14 at 8:30 a.m. EST

MIAMI, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced that the Company will release its third quarter 2022 financial results on Monday, November 14, 2022 before the open of the U.S. financial markets. Management will host a conference call to discuss the Company’s financial results and provide a corporate update on the same day at 8:30 a.m. EST.

Dial-in Number
U.S. Dial-in Number: 844-200-6205
Canada Dial-in Number: 833-950-0062
All Other Locations Dial-in Number: 929-526-1599
Access code: 982246

U.S. Replay Dial-in Number: 866-813-9403
Canada Replay Dial-in Number: 226-828-7578
All Other Locations Dial-in Number: 44-204-525-0658
Conference ID: 329442

An audio webcast of the call may also be accessed from the ‘Investors’ page of the Longeveron website at www.longeveron.com. A replay of the call will be available on the Longeveron website shortly after completion of the call.

About Longeveron Inc.

Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B™, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B™ has a multi-modal mechanism of action that is pro-vascular, pro-regenerative, and anti-inflammatory, promoting tissue repair and healing with broad potential applications across a spectrum of disease areas. Longeveron is advancing Lomecel-B™ through clinical trials in three indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s Disease, and Aging Frailty. Additional information about the Company is available at www.longeveron.com.

Investor Contact:
Elsie Yau
Stern IR, Inc.
212-698-8700
elsie.yau@sternir.com

FAQ

When will Longeveron release its Q3 2022 financial results?

Longeveron will release its Q3 2022 financial results on November 14, 2022.

What time is the Longeveron conference call scheduled?

The conference call is scheduled for 8:30 a.m. EST on November 14, 2022.

How can I access the Longeveron conference call?

You can access the conference call via dial-in numbers or through an audio webcast on the Longeveron website.

What is Lomecel-B™?

Lomecel-B™ is an allogeneic medicinal signaling cell therapy product being developed by Longeveron to address several medical conditions.

What indications is Lomecel-B™ being tested for?

Lomecel-B™ is being tested for Hypoplastic Left Heart Syndrome, Alzheimer's Disease, and Aging Frailty.